semaglutide and kidney problems in patients with overweight or obesity chronic disease without diabetes: a randomized double-blind placebo-controlled clinical trial In the FLOW trial, researchers

What the research shows (& what it doesnt) Potential Benefits Many people lose a significant amount of weight (up to 15% of body weight in some trials) Appetite often decreases, sometimes dramatically Improvements in measures of blood glucose management, cholesterol, and blood pressure have been observed during clinical trials But here's whats also true: Known Risks and Gaps in Knowledge Short-term research : Most studies last no longer than 1-2 years

Beyond weight reduction, the same trial reported several additional metabolic outcomes as secondary or exploratory endpoints: Improved glycaemic control reductions in HbA1c levels were observed in participants with type 2 diabetes in a separate Phase 2 cohort [3] [4] Reduced waist circumference suggesting a decrease in visceral (abdominal) fat, which is associated with cardiovascular risk Improvements in lipid profiles including reductions in triglycerides Potential signal for benefit in metabolic-associated steatotic liver disease (MASLD) based on the glucagon receptor's proposed role in hepatic fat metabolism

Moringa oleifera often called the 'miracle tree' has a long history in traditional medicine, and its leaves are packed with antioxidants, isothiocyanates, and chlorogenic acid

Men using PT-141 off-label may report different efficacy patterns, though nausea remains a common adverse effect in both groups

J., Joyce, P